MTRY - MONTEREY BIO ACQUISITION CORP
This page shows which of the focused investors we track hold MTRY and how their positions changed, so you can see how much conviction the group has in the stock.
In Q2 2022 it was held by 1 manager with an aggregate reported value of $1.5M, which is 0.00% of the combined portfolio.
As of Q2 2022, 1 tracked institutional manager held MTRY (MONTEREY BIO ACQUISITION CORP) with an aggregate reported value of $1.5M — 0.00% of the combined AlphaBaseline portfolio.
Get email alerts when a tracked manager trades MTRY — sign in or create a free account.
- Source
- Curated SEC 13F filings
- Period
- Q2 2022
- Ticker
- MTRY
13F data is delayed and excludes shorts/non-13F assets.
Holders
| 1 | Howard Marks - Oaktree Capital Management | 0.02% | - | 150,000 | $1.5M |
Loading holder history for MTRY…